Guardant Health CEO and leadership

Helmy is a serial entrepreneur and pioneer in the biotech industry. After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) in 2006 to work on low-cost DNA sequencing technologies. At SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-gen sequencing. In 2007, he co-founded Avantome to commercialize a low-cost, high-performance next-gen sequencing platform to seed the democratization of next-gen sequencing. As its founding CEO, he led Avantome through two rounds of financing and through acquisition by Illumina in 2008. At Illumina, Helmy was Sr Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems.

AmirAli is a serial entrepreneur in the sample preparation and clinical research fields. Prior to co-founding Guardant, he was Sr Director of Diagnostics Research at Illumina and led the research efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different sample preparation technologies suitable for clinical applications. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by Illumina in 2009. Prior to his industrial career, he led the Technology Development group at Stanford Genome Technology Center. AmirAli received his PhD in electrical engineering and MSc in management science from Stanford University.

Michael Bell is a Chief Financial Officer at Guardant Health and Chief Financial Officer at CareDx Inc and is based in San Francisco, California. He has worked as Chief Financial Officer & SVP at Singulex Inc, Finance Manager at United Utilities, and Manager at Deloitte. Michael works or has worked as Global Head:Finance at Novartis Diagnostics and FELLOW at ICAEW. He studied at University of Warwick until 1993 and University of Leicester between 1987 and 1990.

Chris Freeman is a Chief Commercial Officer at Guardant Health and is based in San Francisco, California. He has worked as Group Manager, Marketing at Genentech; Director, Cardiopulmonary & Oncology Marketing at GILEAD SCIENCES INC; and Director, Strategic Marketing & Alliance Management at Elan Technologies Inc. Chris works or has worked as Senior Region Director, HIV Sales at GILEAD SCIENCES INC. He studied at Central Michigan University between 1997 and 2000, Golden Gate Industries between 2001 and 2006, and West Point-United States Military Academy between 1992 and 1996.

Craig Eagle is a Board Member at GENEREX BIOTECHNOLOGY CORP, Board Member at ASSURED PHARMACY INC, and Head:Oncology Therapeutic at Pfizer and is based in San Francisco, California. He has worked as VP:Medical Affairs Oncology at Genentech; Board Member at REGENICIN, INC.; and Worldwide Leader at Pfizer. Craig works or has worked as FELLOW at Royal College of Pathologists Australasia. He attended University of New South Wales.

Helmy is a serial entrepreneur and pioneer in the biotech industry. After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) in 2006 to work on low-cost DNA sequencing technologies. At SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-gen sequencing. In 2007, he co-founded Avantome to commercialize a low-cost, high-performance next-gen sequencing platform to seed the democratization of next-gen sequencing. As its founding CEO, he led Avantome through two rounds of financing and through acquisition by Illumina in 2008. At Illumina, Helmy was Sr Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems.

AmirAli is a serial entrepreneur in the sample preparation and clinical research fields. Prior to co-founding Guardant, he was Sr Director of Diagnostics Research at Illumina and led the research efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different sample preparation technologies suitable for clinical applications. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by Illumina in 2009. Prior to his industrial career, he led the Technology Development group at Stanford Genome Technology Center. AmirAli received his PhD in electrical engineering and MSc in management science from Stanford University.

Helmy is a serial entrepreneur and pioneer in the biotech industry. After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) in 2006 to work on low-cost DNA sequencing technologies. At SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-gen sequencing. In 2007, he co-founded Avantome to commercialize a low-cost, high-performance next-gen sequencing platform to seed the democratization of next-gen sequencing. As its founding CEO, he led Avantome through two rounds of financing and through acquisition by Illumina in 2008. At Illumina, Helmy was Sr Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems.

AmirAli is a serial entrepreneur in the sample preparation and clinical research fields. Prior to co-founding Guardant, he was Sr Director of Diagnostics Research at Illumina and led the research efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different sample preparation technologies suitable for clinical applications. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by Illumina in 2009. Prior to his industrial career, he led the Technology Development group at Stanford Genome Technology Center. AmirAli received his PhD in electrical engineering and MSc in management science from Stanford University.